PortalPublikationenSpecific microRNA signatures in exosomes of triple-negative ...

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Standard

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. / Stevic, Ines; Müller, Volkmar; Weber, Karsten; Fasching, Peter A; Karn, Thomas; Marmé, Frederic; Schem, Christian; Stickeler, Elmar; Denkert, Carsten; van Mackelenbergh, Marion; Salat, Christoph; Schneeweiss, Andreas; Pantel, Klaus; Loibl, Sibylle; Untch, Michael; Schwarzenbach, Heidi.

in: BMC MED, Jahrgang 16, Nr. 1, 10.10.2018, S. 179.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stevic, I, Müller, V, Weber, K, Fasching, PA, Karn, T, Marmé, F, Schem, C, Stickeler, E, Denkert, C, van Mackelenbergh, M, Salat, C, Schneeweiss, A, Pantel, K, Loibl, S, Untch, M & Schwarzenbach, H 2018, 'Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial', BMC MED, Jg. 16, Nr. 1, S. 179. https://doi.org/10.1186/s12916-018-1163-y

APA

Stevic, I., Müller, V., Weber, K., Fasching, P. A., Karn, T., Marmé, F., Schem, C., Stickeler, E., Denkert, C., van Mackelenbergh, M., Salat, C., Schneeweiss, A., Pantel, K., Loibl, S., Untch, M., & Schwarzenbach, H. (2018). Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC MED, 16(1), 179. https://doi.org/10.1186/s12916-018-1163-y

Vancouver

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC MED. 2018 Okt 10;16(1):179. https://doi.org/10.1186/s12916-018-1163-y

Bibtex

@article{ce7b8e34d3ba461bb6f6c6e6be73e4f9,
title = "Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial",
abstract = "BACKGROUND: The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC).METHODS: First, miRNA expression profiles were determined in exosomes derived from the plasma of 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based microRNA array card containing 384 different miRNAs. Forty-five miRNAs associated with different clinical parameters were then selected and mounted on microRNA array cards that served for the quantification of exosomal miRNAs in 435 BC patients before therapy and 20 healthy women. Confocal microscopy, Western blot, and ELISA were used for exosome characterization.RESULTS: Quantification of 45 exosomal miRNAs showed that compared with healthy women, 10 miRNAs in the entire cohort of BC patients, 13 in the subgroup of 211 HER2-positive BC, and 17 in the subgroup of 224 TNBC were significantly deregulated. Plasma levels of 18 exosomal miRNAs differed between HER2-positive and TNBC subtypes, and 9 miRNAs of them also differed from healthy women. Exosomal miRNAs were significantly associated with the clinicopathological and risk factors. In uni- and multivariate models, miR-155 (p = 0.002, p = 0.003, respectively) and miR-301 (p = 0.002, p = 0.001, respectively) best predicted pathological complete response (pCR).CONCLUSION: Our findings show a network of deregulated exosomal miRNAs with specific expression patterns in exosomes of HER2-positive and TNBC patients that are also associated with clinicopathological parameters and pCR within each BC subtype.",
keywords = "Journal Article, Research Support, Non-U.S. Gov't",
author = "Ines Stevic and Volkmar M{\"u}ller and Karsten Weber and Fasching, {Peter A} and Thomas Karn and Frederic Marm{\'e} and Christian Schem and Elmar Stickeler and Carsten Denkert and {van Mackelenbergh}, Marion and Christoph Salat and Andreas Schneeweiss and Klaus Pantel and Sibylle Loibl and Michael Untch and Heidi Schwarzenbach",
year = "2018",
month = oct,
day = "10",
doi = "10.1186/s12916-018-1163-y",
language = "English",
volume = "16",
pages = "179",
journal = "BMC MED",
issn = "1741-7015",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

AU - Stevic, Ines

AU - Müller, Volkmar

AU - Weber, Karsten

AU - Fasching, Peter A

AU - Karn, Thomas

AU - Marmé, Frederic

AU - Schem, Christian

AU - Stickeler, Elmar

AU - Denkert, Carsten

AU - van Mackelenbergh, Marion

AU - Salat, Christoph

AU - Schneeweiss, Andreas

AU - Pantel, Klaus

AU - Loibl, Sibylle

AU - Untch, Michael

AU - Schwarzenbach, Heidi

PY - 2018/10/10

Y1 - 2018/10/10

N2 - BACKGROUND: The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC).METHODS: First, miRNA expression profiles were determined in exosomes derived from the plasma of 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based microRNA array card containing 384 different miRNAs. Forty-five miRNAs associated with different clinical parameters were then selected and mounted on microRNA array cards that served for the quantification of exosomal miRNAs in 435 BC patients before therapy and 20 healthy women. Confocal microscopy, Western blot, and ELISA were used for exosome characterization.RESULTS: Quantification of 45 exosomal miRNAs showed that compared with healthy women, 10 miRNAs in the entire cohort of BC patients, 13 in the subgroup of 211 HER2-positive BC, and 17 in the subgroup of 224 TNBC were significantly deregulated. Plasma levels of 18 exosomal miRNAs differed between HER2-positive and TNBC subtypes, and 9 miRNAs of them also differed from healthy women. Exosomal miRNAs were significantly associated with the clinicopathological and risk factors. In uni- and multivariate models, miR-155 (p = 0.002, p = 0.003, respectively) and miR-301 (p = 0.002, p = 0.001, respectively) best predicted pathological complete response (pCR).CONCLUSION: Our findings show a network of deregulated exosomal miRNAs with specific expression patterns in exosomes of HER2-positive and TNBC patients that are also associated with clinicopathological parameters and pCR within each BC subtype.

AB - BACKGROUND: The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC).METHODS: First, miRNA expression profiles were determined in exosomes derived from the plasma of 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based microRNA array card containing 384 different miRNAs. Forty-five miRNAs associated with different clinical parameters were then selected and mounted on microRNA array cards that served for the quantification of exosomal miRNAs in 435 BC patients before therapy and 20 healthy women. Confocal microscopy, Western blot, and ELISA were used for exosome characterization.RESULTS: Quantification of 45 exosomal miRNAs showed that compared with healthy women, 10 miRNAs in the entire cohort of BC patients, 13 in the subgroup of 211 HER2-positive BC, and 17 in the subgroup of 224 TNBC were significantly deregulated. Plasma levels of 18 exosomal miRNAs differed between HER2-positive and TNBC subtypes, and 9 miRNAs of them also differed from healthy women. Exosomal miRNAs were significantly associated with the clinicopathological and risk factors. In uni- and multivariate models, miR-155 (p = 0.002, p = 0.003, respectively) and miR-301 (p = 0.002, p = 0.001, respectively) best predicted pathological complete response (pCR).CONCLUSION: Our findings show a network of deregulated exosomal miRNAs with specific expression patterns in exosomes of HER2-positive and TNBC patients that are also associated with clinicopathological parameters and pCR within each BC subtype.

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1186/s12916-018-1163-y

DO - 10.1186/s12916-018-1163-y

M3 - SCORING: Journal article

C2 - 30301470

VL - 16

SP - 179

JO - BMC MED

JF - BMC MED

SN - 1741-7015

IS - 1

ER -